Dr. Fletcher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
520 Country Club Rd
Eugene, OR 97401
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2018 - 2021
Baylor College of MedicineResidency, Internal Medicine, 2015 - 2018
Keck School of Medicine of the University of Southern CaliforniaClass of 2015
Certifications & Licensure
OR State Medical License 2018 - 2025
TX State Medical License 2017 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsA phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.Sudhir Manda, Bertrand M Anz 3rd, Christopher Benton, E Randolph Broun, Habte A Yimer
Hematological Oncology. 2024-05-01 - 11 citationsGraft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations.Laura F. Newell, Jennifer Dunlap, Ken Gatter, Grover C. Bagby, Richard D. Press
American Journal of Transplantation. 2021-05-07 - 34 citationsIDH Inhibitors in AML—Promise and PitfallsHannah Stowe McMurry, Luke B Fletcher, Elie Traer
Current Hematologic Malignancy Reports. 2021-04-30
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
